EFFICACY DATA

Questions and Ordering? Call 1-800-423-2090
Intended for a US Healthcare Professional Audience Only.

Effective, fast-acting hemostasis1

Ability to measure an objective surrogate marker of hemostasis and coagulation1

6%
Patient Response
[28/28]

24 hrs

Achieved Primary Endpoint1

100% response seen at 24 hours after initial dosing of OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence (n=28)1

  • A positive response is one which was deemed to be either effective or partially effective; that is, bleeding stopped or reduced, with clinical improvement and achievement of specified factor VIII (FVIII) trough levels1
Seperator

Fast-acting1

Response seen within hours1

6%
Patient Response
[19/20]

8 hrs

6%
Patient Response
[18/18]

16 hrs

Fast-acting1

Response seen within hours1

First-line overall treatment success1

  • Overall treatment success was determined by the investigator based on his/her ability to discontinue OBIZUR or reduce the dose and/or dosing frequency of OBIZUR1
flag
Seperator
94%

(16/17) of patients treated with OBIZUR as a first-line treatment achieved overall treatment success1

flag
Seperator

Effective in patients with high-titer FVIII autoantibodies1,3

  • Baseline mean: 84; range: 4-6513

Measuring FVIII activity levels helps determine the dose needed to stop the bleed1

  • Measure response as early as 30 minutes after the initial dose1
  • Identify results after first and all subsequent infusions1